Genprex, Inc. GNPX
We take great care to ensure that the data presented and summarized in this overview for Genprex, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in GNPX
Top Purchases
Top Sells
About GNPX
Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002, a preclinical stage gene therapy for diabetes. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.
Insider Transactions at GNPX
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 05
2024
|
Toscano Jose Antonio Moreno Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,750
+37.71%
|
-
|
|
Dec 05
2024
|
Ryan M. Confer President, CEO and CFO |
BUY
Grant, award, or other acquisition
|
Direct |
29,375
+42.88%
|
-
|
|
Dec 05
2024
|
Brent M Longnecker Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,750
+36.62%
|
-
|
|
Dec 05
2024
|
William R Wilson Jr. Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,750
+37.71%
|
-
|
|
Dec 05
2024
|
Mark Stanley Berger Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
18,250
+44.18%
|
-
|
|
Feb 18
2024
|
Mark Stanley Berger Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,319
-21.53%
|
$5,276
$4.4 P/Share
|
|
Feb 18
2024
|
Ryan M. Confer President, CEO and CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,126
-10.34%
|
$4,504
$4.4 P/Share
|
|
Feb 18
2024
|
John Rodney Varner Chairman, President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
2,642
-9.11%
|
$10,568
$4.4 P/Share
|
|
Jun 27
2023
|
Toscano Jose Antonio Moreno Director |
BUY
Grant, award, or other acquisition
|
Direct |
123,795
+50.0%
|
-
|
|
Jun 27
2023
|
Brent M Longnecker Director |
BUY
Grant, award, or other acquisition
|
Direct |
123,795
+47.14%
|
-
|
|
Jun 27
2023
|
William R Wilson Jr. Director |
BUY
Grant, award, or other acquisition
|
Direct |
123,795
+50.0%
|
-
|
|
Apr 21
2023
|
Catherine M Vaczy EVP GC Chief Strategy Officer |
BUY
Open market or private purchase
|
Direct |
20,000
+7.02%
|
$20,000
$1.07 P/Share
|
|
Apr 21
2023
|
John Rodney Varner Chairman, President and CEO |
BUY
Open market or private purchase
|
Indirect |
19,000
+47.74%
|
$19,000
$1.05 P/Share
|
|
Feb 18
2023
|
Mark Stanley Berger Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
245,000
+50.0%
|
-
|
|
Feb 18
2023
|
Catherine M Vaczy EVP GC Chief Strategy Officer |
BUY
Grant, award, or other acquisition
|
Direct |
245,000
+50.0%
|
-
|
|
Feb 18
2023
|
Ryan M. Confer President, CEO and CFO |
BUY
Grant, award, or other acquisition
|
Direct |
245,000
+36.0%
|
-
|
|
Feb 18
2023
|
Hermant Kumar Chief Mfgr & Tech Officer |
BUY
Grant, award, or other acquisition
|
Direct |
200,000
+50.0%
|
-
|
|
Feb 18
2023
|
John Rodney Varner Chairman, President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
625,000
+35.02%
|
-
|
|
Jul 28
2022
|
Ryan M. Confer President, CEO and CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
116,973
+38.04%
|
$0
$0.02 P/Share
|
|
Apr 05
2021
|
Brent M Longnecker Director |
BUY
Open market or private purchase
|
Direct |
15,000
+50.0%
|
$60,000
$4.15 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 61.9K shares |
|---|
| Payment of exercise price or tax liability | 5.09K shares |
|---|